
ALT Sure! Here's an alternative text description: "Promotional image for a virtual event by Fierce Biotech on November 18, 2026, titled 'Cell and Gene Therapy at a Crossroads: Scaling Innovation, Expanding Access.' Featured speaker is Brian Culley, CEO of Lineage Cell Therapeutics. Includes a headshot of Brian Culley.

ALT WOW! @LineageCell has just announced that the it is expanding its pipeline via the acquisition of NeuroAirmid Therapeutics for 4.7 million dollars - half in cash and half in equity via LCTX shares. The acquisition includes worldwide rights for hNSC-01 - which Lineage renamed HUNT1 - NeuroAirmid’s clinical-stage neural Cell Therapy program for the treatment of Huntington’s Disease (HD), and all of the data from the ongoing REGEN4HD clinical trial. It’s great to see Lineage entering the neural Cell Therapy field and strengthening its clinical pipeline. Kudos to Brian Culley for making this deal!























